J. Folkman, Addressing tumor blood vessels, Nature Biotechnology, vol.92, issue.6, p.510, 1997.
DOI : 10.1016/S0959-8049(96)00376-0

Y. Takahashi, Y. Kitadai, C. Bucana, K. Cleary, and L. Ellis, Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer, Cancer Res, vol.55, issue.18, pp.3964-3968, 1995.

Y. Takebayashi, S. Aklyama, K. Yamada, S. Akiba, and T. Aikou, Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma, Cancer, vol.92, issue.2, pp.226-231, 1996.
DOI : 10.1002/(SICI)1097-0142(19960715)78:2<226::AID-CNCR6>3.0.CO;2-J

R. Radinsky and L. Ellis, Molecular determinants in the biology of liver metastasis, Surg Oncol Clin North Am, vol.5, issue.2, pp.215-229, 1996.

N. Ferrara and T. Davis-smyth, The Biology of Vascular Endothelial Growth Factor, Endocrine Reviews, vol.18, issue.1, pp.4-25, 1997.
DOI : 10.1210/edrv.18.1.0287

A. Gaya and V. Tse, A preclinical and clinical review of aflibercept for the management of cancer, Cancer Treatment Reviews, vol.38, issue.5, pp.484-493, 2012.
DOI : 10.1016/j.ctrv.2011.12.008

C. Sternberg, Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer, Annals of Oncology, vol.19, issue.Supplement 7, pp.91-95, 2008.
DOI : 10.1093/annonc/mdn473

Q. Chu, Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors, Expert Opinion on Biological Therapy, vol.108, issue.2, pp.263-271, 2009.
DOI : 10.1200/JCO.2007.14.7116

A. Lockhart, M. Rothenberg, J. Dupont, W. Cooper, C. P. Sternas et al., Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors, Journal of Clinical Oncology, vol.28, issue.2, pp.207-214, 2009.
DOI : 10.1200/JCO.2009.22.9237

F. Baffert, T. Le, B. Sennino, G. Thurston, C. Kuo et al., Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling, AJP: Heart and Circulatory Physiology, vol.290, issue.2, 2006.
DOI : 10.1152/ajpheart.00616.2005

A. Eichten, A. Adler, B. Cooper, J. Griffith, Y. Wei et al., Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models, Angiogenesis, vol.79, issue.2, pp.429-441, 2012.
DOI : 10.1007/s10456-012-9328-3

G. Freyer, N. Isambert, B. You, S. Zanetta, C. Falandry et al., Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours, British Journal of Cancer, vol.10, issue.4, 2012.
DOI : 10.1158/1078-0432.CCR-06-2553

R. Coleman, L. Duska, P. Ramirez, J. Heymach, A. Kamat et al., Phase 1???2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer, The Lancet Oncology, vol.12, issue.12, pp.1109-1117, 2011.
DOI : 10.1016/S1470-2045(11)70244-3

N. Colombo, G. Mangili, S. Mammoliti, M. Kalling, B. Tholander et al., A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites, Gynecologic Oncology, vol.125, issue.1, pp.42-47, 2012.
DOI : 10.1016/j.ygyno.2011.11.021

R. Ramlau, V. Gorbunova, T. Ciuleanu, S. Novello, M. Ozguroglu et al., Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non???Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial, Journal of Clinical Oncology, vol.30, issue.29, pp.3640-3647, 2012.
DOI : 10.1200/JCO.2012.42.6932

K. He, B. Cui, G. Li, H. Wang, J. K. Teng et al., The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC), OncoTargets and therapy, vol.5, pp.59-65, 2012.

T. Wang and A. Lockhart, Aflibercept in the treatment of metastatic colorectal cancer, 2012.

E. Van-cutsem, J. Tabernero, R. Lakomy, H. Prenen, J. Prausova et al., Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen, Journal of Clinical Oncology, vol.30, issue.28, pp.3499-3506, 2012.
DOI : 10.1200/JCO.2012.42.8201

H. Thai, C. Veyrat-follet, N. Vivier, C. Dubruc, G. Sanderink et al., A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects, British Journal of Clinical Pharmacology, vol.37, issue.7, pp.402-414, 2011.
DOI : 10.1111/j.1365-2125.2011.04015.x
URL : https://hal.archives-ouvertes.fr/inserm-00629806

M. Lavielle, MONOLIX (MOdèles NOn LInéaires à effets miXtes), 2008.

E. Kuhn and M. Lavielle, Maximum likelihood estimation in nonlinear mixed effects models, Computational Statistics & Data Analysis, vol.49, issue.4, pp.1020-1038, 2005.
DOI : 10.1016/j.csda.2004.07.002

A. Samson, M. Lavielle, and F. Mentre, The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model, Statistics in Medicine, vol.13, issue.27, pp.4860-4875, 2007.
DOI : 10.1002/sim.2950
URL : https://hal.archives-ouvertes.fr/hal-00263511

A. Wald, Tests of statistical hypotheses concerning several parameters when the number of observations is large, Transactions of the American Mathematical Society, vol.54, issue.3, pp.426-482, 1943.
DOI : 10.1090/S0002-9947-1943-0012401-3

K. Brendel, E. Comets, C. Laffont, C. Laveille, and F. Mentre, Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide, Pharmaceutical Research, vol.91, issue.9, pp.2036-2049, 2006.
DOI : 10.1007/s11095-006-9067-5
URL : https://hal.archives-ouvertes.fr/inserm-00189557

E. Comets, K. Brendel, and F. Mentre, Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R, Computer Methods and Programs in Biomedicine, vol.90, issue.2, pp.154-166, 2008.
DOI : 10.1016/j.cmpb.2007.12.002
URL : https://hal.archives-ouvertes.fr/inserm-00274332

E. Comets, K. Brendel, and F. Mentré, Model evaluation in nonlinear mixed effect models, with applications to pharmacokinetics, J Soc Fr Stat, vol.151, pp.106-128, 2010.

R. Savic and M. Karlsson, Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions, The AAPS Journal, vol.11, issue.3, pp.558-569, 2009.
DOI : 10.1208/s12248-009-9133-0

D. Mager and W. Jusko, General pharmacokinetic model for drugs exhibiting targetmediated drug disposition, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.6, pp.507-532, 2001.
DOI : 10.1023/A:1014414520282

D. Mager, Target-mediated drug disposition and dynamics, Biochemical Pharmacology, vol.72, issue.1, pp.1-10, 2006.
DOI : 10.1016/j.bcp.2005.12.041

D. Mager and W. Krzyzanski, Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition, Pharmaceutical Research, vol.30, issue.10, pp.1589-1596, 2005.
DOI : 10.1007/s11095-005-6650-0

L. Gibiansky, E. Gibiansky, T. Kakkar, and P. Ma, Approximations of the target-mediated drug disposition model and identifiability of model parameters, Journal of Pharmacokinetics and Pharmacodynamics, vol.63, issue.5, pp.573-591, 2008.
DOI : 10.1007/s10928-008-9102-8

L. Gibiansky and E. Gibiansky, Target-Mediated Drug Disposition: New Derivation of the Michaelis-Menten Model, and Why It Is Often Sufficient for Description of Drugs with TMDD, PAGE, vol.19, 2010.

C. Kut, M. Gabhann, F. Popel, and A. , Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer, British Journal of Cancer, vol.53, issue.7, pp.978-985, 2007.
DOI : 10.1016/j.canlet.2003.09.018

M. Stefanini, F. Wu, M. Gabhann, F. Popel, and A. , A compartment model of VEGF distribution in blood, healthy and diseased tissues, BMC Systems Biology, vol.2, issue.1, p.77, 2008.
DOI : 10.1186/1752-0509-2-77

J. Lu, R. Bruno, S. Eppler, W. Novotny, B. Lum et al., Clinical pharmacokinetics of bevacizumab in patients with solid tumors, Cancer Chemotherapy and Pharmacology, vol.28, issue.5, pp.779-786, 2008.
DOI : 10.1007/s00280-007-0664-8

J. Pinheiro and D. Bates, Mixed-effects models for s and s-plus, 2000.
DOI : 10.1007/978-1-4419-0318-1

G. Verbeke and G. Molenberghs, Linear Mixed Models for Longitudinal Data, 2000.
DOI : 10.1007/978-1-4612-2294-1_3

B. Efron, Bootstrap Methods: Another Look at the Jackknife, The Annals of Statistics, vol.7, issue.1, pp.1-26, 1979.
DOI : 10.1214/aos/1176344552

B. Efron and R. Tibshirani, An introduction to the bootstrap, 1994.
DOI : 10.1007/978-1-4899-4541-9

J. Shao and D. Tu, The jacknife and bootstrap, 1995.

A. Davison and D. Hinkley, Bootstrap methods and their application, 1997.
DOI : 10.1017/CBO9780511802843

J. Mackinnon, Bootstrap Methods in Econometrics*, Economic Record, vol.14, issue.s1, pp.2-18, 2006.
DOI : 10.1214/ss/1063994977

R. Wehrens, H. Putter, B. Lutgarde, and M. , The bootstrap: a tutorial, Chemometrics and Intelligent Laboratory Systems, vol.54, issue.1, pp.35-52, 2000.
DOI : 10.1016/S0169-7439(00)00102-7

J. Ocana, E. Halimi, R. , R. Villa, M. Sanchez et al., Bootstrapping repeated measures data in a nonlinear mixed-models context, Mathematics Preprint Series, vol.367, pp.1-31, 2005.

E. Flachaire, Bootstrapping heteroskedastic regression models: wild bootstrap vs. pairs bootstrap, Computational Statistics & Data Analysis, vol.49, issue.2, pp.361-376, 2005.
DOI : 10.1016/j.csda.2004.05.018
URL : https://hal.archives-ouvertes.fr/halshs-00175910

R. Halimi, Nonlinear mixed-effects models and bootstrap resampling: Analysis of non-normal repeated measures in biostatistical practice, 2005.

S. Das and A. Krishen, Some bootstrap methods in nonlinear mixed-effect models, Journal of Statistical Planning and Inference, vol.75, issue.2, pp.237-245, 1999.
DOI : 10.1016/S0378-3758(98)00145-1

R. Van-der-leeden, F. Busing, and E. Meijer, Bootstrap methods for two-level models, 1997.

H. Wu and J. Zhang, The study of long-term HIV dynamics using semi-parametric non-linear mixed-effects models, Statistics in Medicine, vol.17, issue.23, pp.3655-3675, 2002.
DOI : 10.1002/sim.1317

N. Laird and J. Ware, Random-Effects Models for Longitudinal Data, Biometrics, vol.38, issue.4, pp.963-974, 1982.
DOI : 10.2307/2529876

E. Ette, Stability and Performance of a Population Pharmacokinetic Model, The Journal of Clinical Pharmacology, vol.87, issue.6, pp.486-495, 1997.
DOI : 10.1002/j.1552-4604.1997.tb04326.x

C. Wu and . Jacknife, Jackknife, Bootstrap and Other Resampling Methods in Regression Analysis, The Annals of Statistics, vol.14, issue.4, pp.1261-1295, 1986.
DOI : 10.1214/aos/1176350142

J. Carpenter and J. Bithell, Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians, Statistics in Medicine, vol.35, issue.9, pp.1141-1164, 2000.
DOI : 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F

J. Carpenter, H. Goldstein, and J. Rasbash, A novel bootstrap procedure for assessing the relationship between class size and achievement, Journal of the Royal Statistical Society: Series C (Applied Statistics), vol.9, issue.4, pp.431-443, 2003.
DOI : 10.1111/1467-9876.00415

L. Moulton and S. Zeger, Bootstrapping generalized linear models, Computational Statistics & Data Analysis, vol.11, issue.1, pp.53-63, 1991.
DOI : 10.1016/0167-9473(91)90052-4

B. Efron, The jacknife, the bootstrap and other resampling plans, Society of Industrial and Applied Mathematics, 1982.

J. Wang, J. Carpenter, and M. Kepler, Using SAS to conduct nonparametric residual bootstrap multilevel modeling with a small number of groups, Computer Methods and Programs in Biomedicine, vol.82, issue.2, pp.130-143, 2006.
DOI : 10.1016/j.cmpb.2006.02.006

N. Holford, P. Chan, J. Nutt, K. Kieburtz, I. Shoulson et al., Disease Progression and Pharmacodynamics in Parkinson Disease ??? Evidence for Functional Protection with Levodopa and Other Treatments, Journal of Pharmacokinetics and Pharmacodynamics, vol.61, issue.6 Suppl 3, pp.281-311, 2006.
DOI : 10.1007/s10928-006-9012-6

D. Bates and J. Pinheiro, Computational methods for multilevel models, 1998.

D. Leeuw, J. Meijer, and E. , Handbook of multilevel analysis, chap. Resamling multilevel models, 2007.

E. Ette and P. Williams, Pharmacometrics: the science of quantitative pharmacology, 2007.
DOI : 10.1002/0470087978

M. Karlsson and R. Savic, Diagnosing Model Diagnostics, Clinical Pharmacology & Therapeutics, vol.23, issue.1, pp.17-20, 2007.
DOI : 10.1038/sj.clpt.6100241

M. Chernick, Bootstrap methods: A guide for practitionners and researchers, 2007.

P. Bonate, Pharmacokinetic-pharmacodynamic modeling and simulation, 2011.
DOI : 10.1007/978-1-4419-9485-1

A. Davison and D. Kuonen, An introduction to the bootstrap with applications in R, Statisticial Computing and Statistical Graphics Newsletter, vol.13, issue.1, pp.6-11, 2002.

L. Lindbom, P. Pihlgren, and E. Jonsson, PsN-Toolkit???A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM, Computer Methods and Programs in Biomedicine, vol.79, issue.3, pp.241-257, 2005.
DOI : 10.1016/j.cmpb.2005.04.005

B. Efron, Bootstrap Methods: Another Look at the Jackknife, The Annals of Statistics, vol.7, issue.1, pp.1-26, 1979.
DOI : 10.1214/aos/1176344552

B. Efron and R. Tibshirani, An Introduction to the Bootstrap Chapman & Hall, 1994.

J. Shao and D. Tu, The Jacknife and Bootstrap Springer, 1995.

A. Davison and D. Hinkley, Bootstrap Methods and their Application, 1997.
DOI : 10.1017/CBO9780511802843

J. Mackinnon, Bootstrap Methods in Econometrics*, Economic Record, vol.14, issue.s1, pp.2-18, 2006.
DOI : 10.1214/ss/1063994977

R. Wehrens, H. Putter, and L. Buydens, The bootstrap: a tutorial, Chemometrics and Intelligent Laboratory Systems, vol.54, issue.1, pp.35-52, 2000.
DOI : 10.1016/S0169-7439(00)00102-7

S. Das and A. Krishen, Some bootstrap methods in nonlinear mixed-effect models, Journal of Statistical Planning and Inference, vol.75, issue.2, pp.237-245, 1999.
DOI : 10.1016/S0378-3758(98)00145-1

R. Halimi, Nonlinear Mixed-effects Models and Bootstrap resampling: Analysis of Non-normal Repeated Measures in Biostatistical Practice VDM Verlag, 2005.

R. Van-der-leeden, F. Busing, and E. Meijer, Bootstrap methods for two-level models, 1997.

H. Wu and J. Zhang, The study of long-term HIV dynamics using semi-parametric non-linear mixed-effects models, Statistics in Medicine, vol.17, issue.23, pp.3655-3675, 2002.
DOI : 10.1002/sim.1317

H. Thai, F. Mentre, N. Holford, and C. Veyrat-follet, Comets E (2013) A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models, Pharm Stat

J. Parke, N. Holford, and B. Charles, A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models, Computer Methods and Programs in Biomedicine, vol.59, issue.1, pp.19-29, 1999.
DOI : 10.1016/S0169-2607(98)00098-4

S. Beal and L. Sheiner, NONMEM User's Guide-Part i. User Basic Guide, 1989.

E. Vonesh and V. Chinchilli, Linear and Nonlinear Models for the Analysis of Repeated Measurements Marcel Dekker, 1997.

Z. Ge, P. Bickel, and J. Rice, An approximate likelihood approach to nonlinear mixed effects models via spline approximation, Computational Statistics & Data Analysis, vol.46, issue.4, pp.747-776, 2004.
DOI : 10.1016/j.csda.2003.10.011

B. Delyon, M. Lavielle, and E. Moulines, Convergence of a stochastic approximation version of the em algo, Annal Stat, vol.27, pp.94-128, 1999.

D. Kalman, A Singularly Valuable Decomposition: The SVD of a Matrix, The College Mathematics Journal, vol.27, issue.1, pp.1-23, 1996.
DOI : 10.2307/2687269

E. Ette and L. Onyiah, Estimating inestimable standard errors in population pharmacokinetic studies: The bootstrap with winsorization, European Journal of Drug Metabolism and Pharmacokinetics, vol.41, issue.1, pp.213-237, 2002.
DOI : 10.1007/BF03190460

L. Aarons, M. O. Karlsson, F. Mentre, F. Rombout, J. L. Steimer et al., Role of modelling and simulation in Phase I drug development, European Journal of Pharmaceutical Sciences, vol.13, issue.2, pp.115-122, 2001.
DOI : 10.1016/S0928-0987(01)00096-3

F. Baffert, T. Le, B. Sennino, G. Thurston, C. J. Kuo et al., Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling, AJP: Heart and Circulatory Physiology, vol.290, issue.2, pp.547-559, 2006.
DOI : 10.1152/ajpheart.00616.2005

G. Bergers and D. Hanahan, Modes of resistance to anti-angiogenic therapy, Nature Reviews Cancer, vol.25, issue.8, pp.592-603, 2008.
DOI : 10.1038/nrc2442

P. Bhargava, J. L. Marshall, W. Dahut, N. Rizvi, N. Trocky et al., A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers, Clin Cancer Res, vol.7, pp.3912-3919, 2001.

P. L. Bonate, Pharmacokinetic-pharmacodynamic modeling and simulation, 2011.
DOI : 10.1007/978-1-4419-9485-1

D. Brownstone and R. Valletta, The Bootstrap and Multiple Imputations: Harnessing Increased Computing Power for Improved Statistical Tests, Journal of Economic Perspectives, vol.15, issue.4, pp.129-141, 2001.
DOI : 10.1257/jep.15.4.129

P. Carmeliet, Mechanisms of angiogenesis and arteriogenesis, Nature Medicine, vol.6, issue.4, pp.389-395, 2000.
DOI : 10.1038/74651

J. R. Carpenter, H. Goldstein, and J. Rasbash, A novel bootstrap procedure for assessing the relationship between class size and achievement, Journal of the Royal Statistical Society: Series C (Applied Statistics), vol.9, issue.4, pp.431-443, 2003.
DOI : 10.1111/1467-9876.00415

M. R. Chernick, Bootstrap methods : A Guide for Practitionners and Researchers, 2007.

Q. S. Chu, Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors, Expert Opinion on Biological Therapy, vol.108, issue.2, pp.263-271, 2009.
DOI : 10.1200/JCO.2007.14.7116

L. Claret, P. Girard, P. M. Hoff, E. Van-cutsem, K. P. Zuideveld et al., Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics, Journal of Clinical Oncology, vol.27, issue.25, pp.4103-4108, 2009.
DOI : 10.1200/JCO.2008.21.0807

E. M. Conway, D. Collen, and P. Carmeliet, Molecular mechanisms of blood vessel growth, Cardiovascular Research, vol.49, issue.3, pp.507-521, 2001.
DOI : 10.1016/S0008-6363(00)00281-9

T. Couffinhal, P. Dufourcq, D. Daret, and C. Duplaa, Les m??canismes de l??angiogen??se. Applications m??dicales et th??rapeutiques, La Revue de M??decine Interne, vol.22, issue.11, pp.1064-1082, 2001.
DOI : 10.1016/S0248-8663(01)00472-6

S. Das and A. Krishen, Some bootstrap methods in nonlinear mixed-effect models, Journal of Statistical Planning and Inference, vol.75, issue.2, pp.237-245, 1999.
DOI : 10.1016/S0378-3758(98)00145-1

A. C. Davison and D. V. Hinkley, Bootstrap Methods and their Application, 1997.
DOI : 10.1017/CBO9780511802843

D. Leeuw, J. Meijer, and E. , Handbook of Multilevel Analysis, chap. Resamling multilevel models, 2007.

D. G. Duda, Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer, ISRN Cell Biology, vol.28, issue.1, p.11, 2012.
DOI : 10.1097/PPO.0b013e3181af5e35

B. Efron, Bootstrap Methods: Another Look at the Jackknife, The Annals of Statistics, vol.7, issue.1, pp.1-26, 1979.
DOI : 10.1214/aos/1176344552

B. Efron, Missing Data, Imputation, and the Bootstrap, Journal of the American Statistical Association, vol.82, issue.426, pp.463-475, 1994.
DOI : 10.2307/2290005

B. Efron and R. J. Tibshirani, An Introduction to the Bootstrap, 1994.
DOI : 10.1007/978-1-4899-4541-9

S. M. Eppler, D. L. Combs, T. D. Henry, J. J. Lopez, S. G. Ellis et al., A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans*, Clinical Pharmacology & Therapeutics, vol.72, issue.1, pp.20-32, 2002.
DOI : 10.1067/mcp.2002.126179

E. I. Ette, Comparing non-hierarchical models: Application to non-linear mixed effects modeling, Computers in Biology and Medicine, vol.26, issue.6, pp.505-512, 1996.
DOI : 10.1016/S0010-4825(96)00031-5

E. I. Ette, Stability and Performance of a Population Pharmacokinetic Model, The Journal of Clinical Pharmacology, vol.87, issue.6, pp.486-495, 1997.
DOI : 10.1002/j.1552-4604.1997.tb04326.x

E. I. Ette and L. C. Onyiah, Estimating inestimable standard errors in population pharmacokinetic studies: The bootstrap with winsorization, European Journal of Drug Metabolism and Pharmacokinetics, vol.41, issue.1, pp.213-224, 2002.
DOI : 10.1007/BF03190460

N. Ferrara, Vascular Endothelial Growth Factor: Basic Science and Clinical Progress, Endocrine Reviews, vol.25, issue.4, pp.581-611, 2004.
DOI : 10.1210/er.2003-0027

N. Ferrara, Angiogenesis : From Basic Ccience to Clinical Applications, 2007.
DOI : 10.1201/9781420004373

N. Ferrara and R. S. Kerbel, Angiogenesis as a therapeutic target, Nature, vol.65, issue.7070, pp.967-974, 2005.
DOI : 10.1038/nature04483

J. Folkman, Tumor angiogenesis : therapeutic implications, N Engl J Med, vol.285, pp.1182-1186, 1971.

J. Folkman, Anti-Angiogenesis, Annals of Surgery, vol.175, issue.3, pp.409-416, 1972.
DOI : 10.1097/00000658-197203000-00014

. Food and D. Administration, Guidance for industry : Population pharmacokinetics, 1999.

V. Lenoir, S. Assadourian, K. Soussan-lazard, S. Ziti-ljajic, and P. Fumoleau, Phase i dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours, Br J Cancer, vol.107, pp.598-603, 2012.

J. Gabrielsson and D. Weiner, Pharmacokinetic and Pharmacodynamic Data Analysis : Concepts and Applications, 1999.

A. Gaya and V. Tse, A preclinical and clinical review of aflibercept for the management of cancer, Cancer Treatment Reviews, vol.38, issue.5, pp.484-493, 2012.
DOI : 10.1016/j.ctrv.2011.12.008

L. Gibiansky and E. Gibiansky, Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic???pharmacodynamic modeling of biologics, Expert Opinion on Drug Metabolism & Toxicology, vol.52, issue.7, pp.803-812, 2009.
DOI : 10.1208/aapsj0902020

L. Gibiansky and E. Gibiansky, Target-mediated drug disposition model for drugs that bind to more than one target, Journal of Pharmacokinetics and Pharmacodynamics, vol.63, issue.5, pp.323-346, 2010.
DOI : 10.1007/s10928-010-9163-3

L. Gibiansky and E. Gibiansky, Target-mediated drug disposition : New derivation of the michaelis-menten model, and why it is often sufficient for description of drugs with tmdd, 19th Population Group Approach in Europe, p.2010

R. Halimi, Nonlinear Mixed-effects Models and Bootstrap resampling : Analysis of Nonnormal Repeated Measures in Biostatistical Practice, 2005.

P. Hall, Asymptotic Properties of the Bootstrap for Heavy-Tailed Distributions, The Annals of Probability, vol.18, issue.3, pp.1342-1360, 1990.
DOI : 10.1214/aop/1176990748

D. J. Hicklin and L. M. Ellis, Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis, Journal of Clinical Oncology, vol.23, issue.5, pp.1011-1027, 2005.
DOI : 10.1200/JCO.2005.06.081

F. Hillen and A. W. Griffioen, Tumour vascularization: sprouting angiogenesis and beyond, Cancer and Metastasis Reviews, vol.307, issue.2, pp.489-502, 2007.
DOI : 10.1007/s10555-007-9094-7
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797856

J. Holash, S. Davis, N. Papadopoulos, S. D. Croll, L. Ho et al., VEGF-Trap: A VEGF blocker with potent antitumor effects, Proceedings of the National Academy of Sciences, vol.99, issue.17, pp.11393-11398, 2002.
DOI : 10.1073/pnas.172398299

N. H. Holford, P. L. Chan, J. G. Nutt, K. Kieburtz, and I. Shoulson, Disease Progression and Pharmacodynamics in Parkinson Disease ??? Evidence for Functional Protection with Levodopa and Other Treatments, Journal of Pharmacokinetics and Pharmacodynamics, vol.61, issue.6 Suppl 3, pp.281-311, 2006.
DOI : 10.1007/s10928-006-9012-6

J. G. Ibrahim, H. Chu, and L. M. Chen, Basic Concepts and Methods for Joint Models of Longitudinal and Survival Data, Journal of Clinical Oncology, vol.28, issue.16, pp.2796-2801, 2010.
DOI : 10.1200/JCO.2009.25.0654

R. K. Jain, D. G. Duda, C. G. Willett, D. V. Sahani, A. X. Zhu et al., Biomarkers of response and resistance to antiangiogenic therapy, Nature Reviews Clinical Oncology, vol.14, issue.6, pp.327-338, 2009.
DOI : 10.1038/nrclinonc.2009.63

W. J. Jusko and H. C. Ko, Physiologic indirect response models characterize diverse types of pharmacodynamic effects, Clinical Pharmacology and Therapeutics, vol.56, issue.4, pp.406-419, 1994.
DOI : 10.1038/clpt.1994.155

M. W. Kieran, R. Kalluri, and Y. J. Cho, The VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path Forward, Cold Spring Harbor Perspectives in Medicine, vol.2, issue.12, p.6593, 2012.
DOI : 10.1101/cshperspect.a006593

J. Kim, W. L. Hayton, J. M. Robinson, and C. L. Anderson, Kinetics of FcRn-mediated recycling of IgG and albumin in human: Pathophysiology and therapeutic implications using a simplified mechanism-based model, Clinical Immunology, vol.122, issue.2, pp.146-155, 2007.
DOI : 10.1016/j.clim.2006.09.001

E. Kuhn and M. Lavielle, Maximum likelihood estimation in nonlinear mixed effects models, Computational Statistics & Data Analysis, vol.49, issue.4, pp.1020-1058, 2005.
DOI : 10.1016/j.csda.2004.07.002

T. T. Kuo and V. G. Aveson, Neonatal Fc receptor and IgG-based therapeutics, mAbs, vol.15, issue.5, pp.422-430, 2011.
DOI : 10.1126/science.287.5456.1279
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225846

C. Kut, M. Gabhann, F. Popel, and A. S. , Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer, British Journal of Cancer, vol.53, issue.7, pp.978-985, 2007.
DOI : 10.1016/j.canlet.2003.09.018

R. L. Lalonde, K. G. Kowalski, M. M. Hutmacher, W. Ewy, D. J. Nichols et al., Model-based Drug Development, Clinical Pharmacology & Therapeutics, vol.33, issue.1, pp.21-32, 2007.
DOI : 10.1038/sj.clpt.6100235

M. Lavielle, MONOLIX (MOdèles NOn LInéaires à effets miXtes). MONOLIX group, 2008.

J. W. Lee, M. Kelley, L. E. King, J. Yang, H. Salimi-moosavi et al., Bioanalytical Approaches to Quantify ???Total??? and ???Free??? Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development, The AAPS Journal, vol.13, issue.1, pp.99-110, 2011.
DOI : 10.1208/s12248-011-9251-3

D. W. Leung, G. Cachianes, W. J. Kuang, D. V. Goeddel, and N. Ferrara, Vascular endothelial growth factor is a secreted angiogenic mitogen, Science, vol.246, issue.4935, pp.1306-1309, 1989.
DOI : 10.1126/science.2479986

G. Levy, Pharmacologic target-mediated drug disposition, Clinical Pharmacology & Therapeutics, vol.56, issue.3, pp.248-252, 1994.
DOI : 10.1038/clpt.1994.134

J. Li, M. G. Wientjes, and J. L. Au, Pancreatic Cancer: Pathobiology, Treatment Options, and Drug Delivery, The AAPS Journal, vol.12, issue.2, pp.223-232, 2010.
DOI : 10.1208/s12248-010-9181-5

S. Loges, T. Schmidt, and P. Carmeliet, Mechanisms of Resistance to Anti-Angiogenic Therapy and Development of Third-Generation Anti-Angiogenic Drug Candidates, Genes & Cancer, vol.1, issue.1, pp.12-25, 2010.
DOI : 10.1177/1947601909356574

T. Louis, Finding the observed information matrix when using the em algorithm, J R Stat Soc Series B, vol.44, pp.226-233, 1982.

J. F. Lu, R. Bruno, S. Eppler, W. Novotny, B. Lum et al., Clinical pharmacokinetics of bevacizumab in patients with solid tumors, Cancer Chemotherapy and Pharmacology, vol.28, issue.5, pp.779-786, 2008.
DOI : 10.1007/s00280-007-0664-8

J. B. Mackinnon, Bootstrap Methods in Econometrics*, Economic Record, vol.14, issue.s1, pp.2-18, 2006.
DOI : 10.1214/ss/1063994977

D. E. Mager, Target-mediated drug disposition and dynamics, Biochemical Pharmacology, vol.72, issue.1, pp.1-10, 2006.
DOI : 10.1016/j.bcp.2005.12.041

D. E. Mager and W. J. Jusko, General pharmacokinetic model for drugs exhibiting targetmediated drug disposition, Journal of Pharmacokinetics and Pharmacodynamics, vol.28, issue.6, pp.507-532, 2001.
DOI : 10.1023/A:1014414520282

D. E. Mager and W. Krzyzanski, Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition, Pharmaceutical Research, vol.30, issue.10, pp.1589-1596, 2005.
DOI : 10.1007/s11095-005-6650-0

D. E. Mager, B. Neuteboom, C. Efthymiopoulos, A. Munafo, and W. J. Jusko, Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Interferon-??1a in Monkeys, Journal of Pharmacology and Experimental Therapeutics, vol.306, issue.1, pp.262-270, 2003.
DOI : 10.1124/jpet.103.049502

J. Parke, N. H. Holford, and B. G. Charles, A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models, Computer Methods and Programs in Biomedicine, vol.59, issue.1, pp.19-29, 1999.
DOI : 10.1016/S0169-2607(98)00098-4

J. C. Pinheiro and D. M. Bates, Mixed-effects models for S and S-plus, 2000.
DOI : 10.1007/978-1-4419-0318-1

R. Development and C. Team, R : A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, 2008.

R. Ramlau, V. Gorbunova, T. E. Ciuleanu, S. Novello, M. Ozguroglu et al., Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non???Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial, Journal of Clinical Oncology, vol.30, issue.29, pp.3640-3647, 2012.
DOI : 10.1200/JCO.2012.42.6932

A. Rapisarda and G. Melillo, Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia, Nature Reviews Clinical Oncology, vol.8, issue.7, pp.378-390, 2012.
DOI : 10.1038/nrclinonc.2012.64

B. Bernard, A. Idbaih, D. Psimaras, L. Dainese, J. Pallud et al., A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy, Clin Cancer Res, vol.18, pp.5071-5080, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00744626

A. Samson, M. Lavielle, and F. Mentre, Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model, Computational Statistics & Data Analysis, vol.51, issue.3, pp.1562-1574, 2006.
DOI : 10.1016/j.csda.2006.05.007
URL : https://hal.archives-ouvertes.fr/inserm-00182360

R. Satchi-fainaro, R. Duncan, and C. Barnes, Polymer Therapeutics for Cancer: Current Status and Future Challenges, Adv Polym Sci, vol.193, pp.1-65, 2006.
DOI : 10.1007/12_024

A. M. Segrave, D. E. Mager, S. A. Charman, G. A. Edwards, and C. J. Porter, Pharmacokinetics of Recombinant Human Leukemia Inhibitory Factor in Sheep, Journal of Pharmacology and Experimental Therapeutics, vol.309, issue.3, pp.1085-1092, 2004.
DOI : 10.1124/jpet.103.063289

J. Shao and D. Tu, The Jacknife and Bootstrap, 1995.

L. Sheiner and S. Beal, NONMEM Version 51, 1998.

R. Sophie, A. Akhtar, Y. Sepah, M. Ibrahim, M. Bittencourt et al., Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases, Biologics in Therapy, vol.24, issue.1, pp.1-22, 2012.
DOI : 10.1007/s13554-012-0003-4

H. T. Thai, F. Mentre, N. H. Holford, C. Veyrat-follet, and E. Comets, A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models, Pharmaceutical Statistics, vol.79, issue.3, 2013.
DOI : 10.1002/pst.1561
URL : https://hal.archives-ouvertes.fr/inserm-00881820

H. T. Thai, C. Veyrat-follet, N. Vivier, C. Dubruc, G. Sanderink et al., A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects, British Journal of Clinical Pharmacology, vol.37, issue.7, pp.402-414, 2011.
DOI : 10.1111/j.1365-2125.2011.04015.x
URL : https://hal.archives-ouvertes.fr/inserm-00629806

L. S. Tham, L. Wang, R. A. Soo, S. C. Lee, H. S. Lee et al., A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non-Small Cell Lung Cancer Patients, Clinical Cancer Research, vol.14, issue.13, pp.4213-4218, 2008.
DOI : 10.1158/1078-0432.CCR-07-4754

A. A. Tsiatis and M. Davidian, Joint modeling of longitudinal and time-to-event data : an overview, Stat Sinica, vol.14, pp.809-834, 2004.

R. Van-der-leeden, F. M. Busing, and E. Meijer, Bootstrap methods for two-level models, 1997.

E. F. Vonesh, A note on the use of Laplace's approximation for nonlinear mixed-effects models, Biometrika, vol.83, issue.2, pp.447-452, 1996.
DOI : 10.1093/biomet/83.2.447

P. Wang, W. Shen, and M. E. Boye, Joint modeling of longitudinal outcomes and survival using latent growth modeling approach in a mesothelioma trial, Health Services and Outcomes Research Methodology, vol.14, issue.2-3, pp.182-199, 2012.
DOI : 10.1007/s10742-012-0092-z

Y. Wang, C. Sung, C. Dartois, R. Ramchandani, B. P. Booth et al., Elucidation of relationship between tumor size and survival in non-smallcell lung cancer patients can aid early decision making in clinical drug development

R. Wehrens, H. Putter, and L. M. Buydens, The bootstrap: a tutorial, Chemometrics and Intelligent Laboratory Systems, vol.54, issue.1, pp.35-52, 2000.
DOI : 10.1016/S0169-7439(00)00102-7

S. Woo, W. Krzyzanski, and W. J. Jusko, Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO), Journal of Pharmacokinetics and Pharmacodynamics, vol.29, issue.Suppl 3, pp.849-868, 2007.
DOI : 10.1007/s10928-007-9074-0

H. Wu and J. T. Zhang, The study of long-term HIV dynamics using semi-parametric non-linear mixed-effects models, Statistics in Medicine, vol.17, issue.23, pp.3655-3675, 2002.
DOI : 10.1002/sim.1317

A. Yafune and M. Ishiguro, Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. I: a use of bootstrap standard error, Statistics in Medicine, vol.82, issue.5, pp.581-599, 1999.
DOI : 10.1002/(SICI)1097-0258(19990315)18:5<581::AID-SIM47>3.0.CO;2-1

G. D. Yancopoulos, S. Davis, N. W. Gale, J. S. Rudge, S. J. Wiegand et al., Vascular-specific growth factors and blood vessel formation, Nature, vol.407, issue.6801, pp.242-248, 2000.
DOI : 10.1038/35025215